Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC
SHANGHAI, Sept. 18, 2024 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of the ESMO 2024 Best Poster Award on September 16, 2024. The award was received for the presentation titled "Updated Safety and Efficacy of Irpagratinib (ABSK011) in advanced hepatocell...
50% ORR: Impressive Clinical Trial Data for Irpagratinib Combined with Atezolizumab in Advanced Hepatocellular Carcinoma Stuns ESMO-GI Congress
SHANGHAI, June 27, 2024 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced that it has presented new phase II clinical data of its highly selective FGFR4 inhibitor irpagratinib (ABSK011) in combination with atezolizumab for the treatment of advanced hepatocellular carc...
Abbisko Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib
SHANGHAI, April 8, 2024 /PRNewswire/ -- 9 April 2024 (Beijing Time), Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced the completion of patient enrollment for its pivotal Phase III trial, MANEUVER (ABSK021-301) STUDY, for evaluating the efficacy and safety of pimicotinib in patient...
Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib （ABSK021）
SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- On January 9, 2024 (Beijing Time), Abbisko Therapeutics (HKEX code: 02256) announced that its investigational innovative CSF-1R inhibitor pimicotinib（ABSK021） has been granted orphan drug designation（ODD） by the European Medicines Agency (EMA) for the treatm...
Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimicotinib (ABSK021)
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") today announced that its CSF-1R inhibitor pimicotinib (ABSK021) has been granted the fast track designation ("FTD") by the U.S. FDA for the treatment of tenosynovial giant cell tumor ("TGCT") patients ...
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck
SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt,Germany. Under the terms of the agreement, Merck will be granted an exclusive licens...
87.5% ORR | Abbisko presented two clinical updates of Pimicotinib at the 2023 CTOS Annual Meeting
SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that two major clinical updates of its CSF-1R inhibitor pimicotinib（ABSK021）were presented at the 2023 Connective Tissue Oncology Society Annual Meeting, which is held inIreland from...
Abbisko will debut two blockbuster clinical research results at the 2023 European Society for Medical Oncology（ESMO）
SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that the clinical results of first-in-human study of FGFR4 inhibitor Irpagratinib（ABSK011）and the clinical results of first-in-human dose-escalating of PD-L1 inhibitor ABSK043 with...
Abbisko presented two preclinical research results at the 35th International Molecular Targets and Cancer Treatment Conference (EORTC-NCI-AACR)
SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko" hereafter) announced that the results of the company's two preclinical studies published at the 35th International Molecular Targets and Cancer Treatment Conference (EORTC) be held inBoston, U.S.. These two research...
77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting
SHANGHAI, May 28, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that the updated results of Phase Ib study of its CSF-1R inhibitor Pimicotinib (ABSK021) in treating patients with advanced tenosynovial giant cell tumor ("TGCT"), will be rele...
Abbisko presents the research results of 5 programs at the 2023 AACR Annual Meeting
SHANGHAI, April 17, 2023 /PRNewswire/ -- Abbisko (Stock Code: 2256.HK)
announced the results of five latest preclinical studies at the 2023 American
Association for Cancer Research (AACR) annual meeting.
The FDA has approved the CSF-1R inhibitor Pimicotinib (ABSK021) of Abbisko Therapeutics to enter the Pivotal Global Multi-center Phase III Clinical Trial
This is the first-ever global phase III trial for TGCT approved by NMPA and FDA. Pimicotinib（ABSK021）was granted BTD by FDA and CDE, discovered and developed byChina biotech。 SHANGHAI, March 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256. HK, referred to as "Abbis...
Abbisko Therapeutics Announces an Out-License Agreement with Allist for ABK3376
SHANG HAI, March 2, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that it has entered into an exclusive Out-License Agreement (the "Agreement" hereafter) with Shanghai Allist Pharmaceuticals Co., Ltd., ("Allist" hereafter) for the further ...
Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib（ABSK021）
SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that its CSF-1R inhibitor Pimicotinib（ABSK021）has been granted the breakthrough therapy designation from FDA for the treatment of tenosynovial giant cell tumor (TGCT) patients...
Abbisko Therapeutics Obtains Approval from The China NMPA to Conduct a Phase II Clinical Study of Pimicotinib (ABSK021） in cGVHD
SHANGHAI, Jan. 18, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that its CSF-1R inhibitor, pimicotinib (ABSK021), has been approved by the National Medical Products Administration ("NMPA") of the People's Republic ofChina for a phase II c...
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061
SHANGHAI, July 4, 2022 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256.HK, referred to "Abbisko Therapeutics" hereafter) today announced completion of dosing of the first patient in the Phase 1 clinical trial in advanced solid tumors for ABSK061, which becomes the first high...
Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules
SHANGHAI, Jan. 17, 2022 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter), a subsidiary of Abbisko Cayman Limited (Stock Code: 2256.HK), today announced that it has entered into a worldwide collaboration and exclusive licensing agreement (the "Agreement") with Eli ...
Qiming's Portfolio Company Abbisko Lists on Main Board of HKEx
SHANGHAI, Oct. 15, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company Abbisko (SEHK:2256), a clinical-stage biopharmaceutical company, listed on the main board of the Hong Kong Stock Exchange onOctober 13. The issue price isHK$ 12.46 per share, representing a market cap of HK$ 8.753 ...
